GlassScriptPhysician profile
Omar Akhtar
NPI 1902093081
$1,393.15
in general payments reported to CMS, 2019-2025
15 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $183 · 2021: $110 · 2022: $231 · 2023: $109 · 2024: $119 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $347.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $354.93 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Medtronic Minimed, INC. | $292.16 | 2019-2020 | |
| Dexcom, INC. | $231.11 | 2019-2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $137.26 | 2019-2025 | Wegovy |
| Amgen INC. | $98.05 | 2019-2020 | |
| Mannkind Corporation | $59.40 | 2019 | |
| Abbott Laboratories | $54.13 | 2024-2025 | Freestyle Libre 3 |
| Insulet Corporation | $47.28 | 2019-2024 | Omnipod |
| Radius Health, INC. | $21.21 | 2021 | |
| Tandem Diabetes Care, INC. | $20.28 | 2022 | |
| Lilly USA, LLC | $19.67 | 2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.41 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.77 | 2022 | |
| Shire North American Group INC | $13.38 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Akhtar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.